Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.Material type: TextPublisher: New York : Alfred A. Knopf, 2018Copyright date: �2018Edition: First editionDescription: x, 339 pages ; 25 cmContent type: text Media type: unmediated Carrier type: volumeISBN: 9781524731656; 152473165XOther title: Secrets and lies in a Silicon Valley startupSubject(s): Holmes, Elizabeth, 1984- | Theranos (Firm) -- History | Hematologic equipment industry -- United States | New business enterprises -- Corrupt practices -- United States -- Cases | Securities fraud -- United States -- CasesGenre/Form: History.DDC classification: 338.7/681761 LOC classification: HD9995.H423 | U627 2018
|Item type||Current location||Collection||Call number||Status||Date due||Barcode||Item holds|
|Book||Downtown Branch Adult non-fiction||Adult non-fiction||338.7681 CAR (Browse shelf)||Checked out||07/24/2020||31562016934905|
|Book||Madison Branch Adult non-fiction||Adult non-fiction||BUS 338.7681 CAR (Browse shelf)||Available||31562016902951|
|Book||Monrovia Branch Adult non-fiction||Adult non-fiction||338.7681 CAR (Browse shelf)||Available||31562016985089|
Includes bibliographical references (pages 305-324) and index.
A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.